• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Notable Labs to Participate in Fireside Chat at the Citizens JMP Securities Life Sciences Conference 2024

    5/9/24 4:05:00 PM ET
    $NTBL
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $NTBL alert in real time by email

    FOSTER CITY, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- Notable Labs, Ltd. (NASDAQ:NTBL) ("Notable", "Notable Labs" or the "Company"), a clinical-stage precision oncology company developing new cancer therapies identified by its Predictive Medicine Platform (PMP), today announced that Thomas Bock, M.D., Chief Executive Officer of Notable Labs, will participate in a fireside chat at the Citizens JMP Securities Life Sciences Conference 2024, taking place on May 13-14, 2024, in New York City.

    Presentation Details:

    Date:Monday, May 13, 2024
    Time:12:30pm EST
    Format:Fireside Chat
    Webcast:Link
      

    A live webcast of the fireside chat can be accessed under "Investor Events & Presentations" on the Notable website at www.notablelabs.com. A replay of the webcast will be available on the Company's website for approximately 90 days.

    About Notable Labs, Ltd.

    Notable Labs, Ltd. Is a clinical-stage platform therapeutics company developing predictive medicines for patients with cancer. Through its proprietary Predictive Medicine Platform (PMP), Notable aims to predict whether or not a patient is likely to respond to a specific therapeutic. The PMP is designed to identify and select clinically responsive patients prior to their treatment, potentially fast-tracking clinical development. By continually advancing and expanding the reach of the PMP across diseases and predicted medical outcomes, Notable aims to be the leader in predictive medicine and revolutionize the way patients seek and receive treatments that work best for them.

    Notable believes it has created a targeted and de-risked in-licensing strategy to deliver a product's medical impact and commercial value faster, with a greater likelihood of success, than traditional drug development. By transforming historical standards of care, Notable aims to create a dramatically positive impact for patients and the healthcare community. Notable is headquartered in Foster City, California. Learn more at our website and follow us @notablelabs.

    CONTACTS:

    Investor Relations:

    Daniel Ferry

    LifeSci Advisors

    +1 (617) 430-7576

    [email protected]



    Primary Logo

    Get the next $NTBL alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $NTBL

    DatePrice TargetRatingAnalyst
    9/20/2024Mkt Outperform → Mkt Perform
    JMP Securities
    More analyst ratings

    $NTBL
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    New insider Zagger Kaile A. claimed no ownership of stock in the company (SEC Form 3)

    3 - Notable Labs, Ltd. (0001603207) (Issuer)

    9/26/24 11:07:19 AM ET
    $NTBL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Patsi Tuomo was granted 65,247 units of Ordinary Shares (SEC Form 4)

    4 - Notable Labs, Ltd. (0001603207) (Issuer)

    5/10/24 5:18:35 PM ET
    $NTBL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Wagner Joseph P

    4 - Notable Labs, Ltd. (0001603207) (Issuer)

    5/10/24 5:17:04 PM ET
    $NTBL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NTBL
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Notable Labs downgraded by JMP Securities

    JMP Securities downgraded Notable Labs from Mkt Outperform to Mkt Perform

    9/20/24 7:46:25 AM ET
    $NTBL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NTBL
    SEC Filings

    View All

    Notable Labs Ltd. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

    8-K - Notable Labs, Ltd. (0001603207) (Filer)

    10/16/24 4:30:30 PM ET
    $NTBL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Notable Labs Ltd. filed SEC Form 8-K: Bankruptcy or Receivership, Leadership Update

    8-K - Notable Labs, Ltd. (0001603207) (Filer)

    10/15/24 6:13:51 AM ET
    $NTBL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Notable Labs Ltd. filed SEC Form 8-K: Costs Associated with Exit or Disposal Activities

    8-K - Notable Labs, Ltd. (0001603207) (Filer)

    9/19/24 4:05:18 PM ET
    $NTBL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NTBL
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Notable Labs to Present Data on September 4th at SOHO 2024

    Society of Hematologic Oncology (SOHO) session to highlight volasertib program Phase 2 volasertib AML program expected to begin in the coming months FOSTER CITY, Calif., Aug. 29, 2024 (GLOBE NEWSWIRE) -- Notable Labs, Ltd. (NASDAQ:NTBL) ("Notable", "Notable Labs" or the "Company"), a clinical-stage precision oncology company developing new cancer therapies identified by its Predictive Medicine Platform (PMP), announced that the Company will present an overview of the Phase 2 program and additional data from preclinical studies evaluating volasertib for acute myeloid leukemia (AML) at the twelfth annual meeting of the Society for Hematologic Oncology (SOHO 2024), b

    8/29/24 7:30:00 AM ET
    $NTBL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Notable Labs Announces CEO Transition

    Thomas Bock, MD resigns as CEO; Joseph Wagner, PhD, CSO, appointed interim CEO Company affirms plan to initiate volasertib Phase 2 program in the coming months FOSTER CITY, Calif., Aug. 26, 2024 (GLOBE NEWSWIRE) -- Notable Labs, Ltd. (NASDAQ:NTBL) ("Notable", "Notable Labs" or the "Company"), a clinical-stage precision oncology company developing new cancer therapies identified by its Predictive Medicine Platform (PMP), announced that Thomas A. Bock, MD has resigned from his positions as Chief Executive Officer (CEO) and member of the Board of Directors of the Company, effective today. Joseph Wagner, PhD, the Company's Chief Scientific Officer (CSO), has been appointed as interim CEO. T

    8/26/24 4:05:00 PM ET
    $NTBL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Notable Labs Receives FDA Clearance to Proceed Further with Volasertib Phase 2 Study

    FOSTER CITY, Calif., July 24, 2024 (GLOBE NEWSWIRE) -- Notable Labs, Ltd. (NASDAQ:NTBL) ("Notable", "Notable Labs" or the "Company"), a clinical-stage precision oncology company developing new cancer therapies identified by its Predictive Medicine Platform (PMP), today announced progress for the Phase 2 volasertib program following receipt of "Clearance to Proceed" from the FDA and agreement on the dosing plan for its Phase 2 clinical trial. With trial start-up activities launched in the first quarter of this year, Notable intends to initiate enrollment in the Phase 2 study for PMP-enabled development of volasertib for relapsed refractory (R/R) acute myeloid leukemia (AML) in the coming mo

    7/24/24 7:30:00 AM ET
    $NTBL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NTBL
    Leadership Updates

    Live Leadership Updates

    View All

    Notable Labs Announces CEO Transition

    Thomas Bock, MD resigns as CEO; Joseph Wagner, PhD, CSO, appointed interim CEO Company affirms plan to initiate volasertib Phase 2 program in the coming months FOSTER CITY, Calif., Aug. 26, 2024 (GLOBE NEWSWIRE) -- Notable Labs, Ltd. (NASDAQ:NTBL) ("Notable", "Notable Labs" or the "Company"), a clinical-stage precision oncology company developing new cancer therapies identified by its Predictive Medicine Platform (PMP), announced that Thomas A. Bock, MD has resigned from his positions as Chief Executive Officer (CEO) and member of the Board of Directors of the Company, effective today. Joseph Wagner, PhD, the Company's Chief Scientific Officer (CSO), has been appointed as interim CEO. T

    8/26/24 4:05:00 PM ET
    $NTBL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NTBL
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Notable Labs Ltd.

    SC 13D/A - Notable Labs, Ltd. (0001603207) (Subject)

    8/9/24 4:01:56 PM ET
    $NTBL
    Biotechnology: Pharmaceutical Preparations
    Health Care